Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:0
članak: 8 od 293  
Back povratak na rezultate
Vojnosanitetski pregled
2018, vol. 75, br. 12, str. 1233-1236
jezik rada: engleski
vrsta rada: prikaz slučaja
doi:10.2298/VSP161026015R

Creative Commons License 4.0
Autoimunska manifestacija infekcije virusom hepatitisa C kao rizik od kasnog virusološkog relapsa posle terapije pegilovanim interferonom i ribavirinom
aClinical Center of Vojvodina, Clinic for Infectious Diseases, Novi Sad + University of Novi Sad, Faculty of Medicine
bClinical Center of Vojvodina, Center for Laboratory Medicine, Novi Sad

e-adresa: ANJA.STOJSIN@mf.uns.ac.rs

Sažetak

Uvod. Iskustvo u lečenju hepatitis C virus (HCV) infekcije pegilovanim interferonom alfa (PegIFNα) i ribavirinom (RBV) ukazuje na postojanje rizika od kasnog virusološkog relapsa' (late virological response - LVR) - ponovna detekcija HCV ribonukleinske kiseline (RNA) u serumu godinama nakon uspostavljanja stabilnog virušološkog odgovora - sustained virological response (SVR). Prikazana su tri bolesnika sa LVR lečena PegIFNα i ribavirinom pet godina nakon uspostavljanja SVR. Prikaz bolesnika. Analizirano je ukupno 129 bolesnika (38,8% ženskog, 61,2% muškog pola, prosečna starost 37,02 ± 11,99 godina) lečenih od hroničnog HCV PegIFNα + RBV, kod kojih je prošlo najmanje pet godina od uspostavljanja SVR. Pored biohemijskih parametara funkcije jetre, rađen je kvalitativni lančane reakcije polimeraze (PCR) HCV RNA test, odnosno kvantitativni PCR HCV RNA test. Pet godina od uspostavljanja SVR kod tri (2,3%) bolesnika je kvalitativnim i kvantitativnim testom PCR HCV RNA utvrđen relaps HCV infekcije. Sva tri bolesnika imala su i pridružene autoimunske bolesti: vaskulitis, autoimunski hepatitis i vaskulitis centralnog nervnog sistema. Zaključak. Potvrđeno je postojanja LVR HCV infekcije prvenstveno kod bolesnika sa pridruženim autoimunskim bolestima. Stoga SVR nakon terapije PegIFNα + RBV treba shvatiti kao pokazatelja uspešne HCV supresije, a ne potpune eradikacije HCV.

Ključne reči

Reference

Castillo, I., Rodriguez-Inigo, E., Lopez-Alcorocho, J. M., Pardo, M., Bartolome, J., Carreno, V. (2006) Hepatitis C Virus Replicates in the Liver of Patients Who Have a Sustained Response to Antiviral Treatment. Clinical Infectious Diseases, 43(10): 1277-1283
Cunningham, E.B., Applegate, T.L., Lloyd, A.R., Dore, G.J., Grebely, J. (2015) Mixed HCV infection and reinfection in people who inject drugs-impact on therapy. Nature Reviews Gastroenterology & Hepatology, 12(4): 218-230
Djukanović, L., Aksić-Miličević, B., Antić, M., Baković, J., Varga, Ž., Gojaković, B., Dimković, N., Ðorđević, V., Ðorđević, V., Ðurić, S., Ðurić, S., Zec, N., Jelačić, R., Kovačević, Z., Lazarević (2012) Epidemiology of end-stage renal disease and hemodialysis treatment in Serbia at the turn of the millennium. Hemodialysis International, 16(4): 517-525
European Association for the Study of the Liver (2015) EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 63(1): 199-236
Formann, E., Steindl-Munda, P., Hofer, H., Jessner, W., Bergholz, U., Gurguta, C., Ferenci, P. (2006) Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Alimentary Pharmacology and Therapeutics, 23(4): 507-511
Fujii, H., Itoh, Y., Ohnishi, N., Sakamoto, M., Ohkawara, T., Sawa, Y., Nishida, K., Nishimura, T., Yamaguchi, K., Yasui, K., Minami, M., Okanoue, T., Ohkawara, Y., Yoshikawa, T. (2010) Relapse of hepatitis C in a pegylated-interferon-α-2b plus ribavirin-treated sustained virological responder. Hepatology Research, 40(6): 654-660
George, S.L., Bacon, B.R., Brunt, E.M., Mihindukulasuriya, K.L., Hoffmann, J., di Bisceglie, A.M. (2008) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients. Hepatology, 49(3): 729-738
Gordon, C.E., Balk, E.M., Becker, B.N., Crooks, P.A., Jaber, B.L., Johnson, C.A., Michael, M.A., Pereira, B.J.G., Uhlig, K., Levin, A. (2008) KDOQI US Commentary on the KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in CKD. American Journal of Kidney Diseases, 52(5): 811-825
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., Razavi, H. (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology, 61(1): S45-S57
Larrubia, J. (2015) Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World Journal of Gastroenterology, 21(12): 3480
Lin, A., Thadareddy, A., Goldstein, M.J., Lake-Bakaar, G. (2008) Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. Journal of Medical Virology, 80(10): 1720-1722
Manns, M. P., Pockros, P. J., Norkrans, G., Smith, C. I., Morgan, T. R., Häussinger, D., Shiffman, M. L., Hadziyannis, S. J., Schmidt, W. N., Jacobson, I. M., Bárcena, R., Schiff, E. R., Shaikh, O. S., Bacon, B., Marcellin, P., Deng, W., Esteban-Mur, R. (2013) Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. Journal of Viral Hepatitis, 20(8): 524-529
Marciano, S. (2015) Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. World Journal of Hepatology, 7(4): 703
Morisco, F. (2013) Sustained virological response: A milestone in the treatment of chronic hepatitis C. World Journal of Gastroenterology, 19(18): 2793
Namikawa, M., Kakizaki, S., Yata, Y., Yamazaki, Y., Horiguchi, N., Sato, K., Takagi, H., Mori, M. (2011) Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. Journal of Gastroenterology and Hepatology, 27(1): 69-75
Pawlotsky, J. (2006) Therapy of hepatitis C: From empiricism to eradication. Hepatology, 43(S1): S207-S220
Pham, T.N., Michalak, T.I. (2011) Occult Hepatitis C Virus Infection and Its Relevance in Clinical Practice. Journal of Clinical and Experimental Hepatology, 1(3): 185-189
Radkowski, M., Gallegos-Orozco, J.F., Jablonska, J., Colby, T.V., Walewska-Zielecka, B., Kubicka, J., Wilkinson, J., Adair, D., Rakela, J., Laskus, T. (2005) Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology, 41(1): 106-114
Rosen, H.R. (2013) Emerging concepts in immunity to hepatitis C virus infection. Journal of Clinical Investigation, 123(10): 4121-4130
Swain, M.G., Lai, M., Shiffman, M.L., Cooksley, G.W.E., Zeuzem, S., Dieterich, D.T., Abergel, A., Pessôa, M.G., Lin, A., Tietz, A., Connell, E.V., Diago, M. (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology, 139(5): 1593-601
Tsuda, N., Yuki, N., Mochizuki, K., Nagaoka, T., Yamashiro, M., Omura, M., Hikiji, K., Kato, M. (2004) Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. Journal of Medical Virology, 74(3): 406-413
Uyanikoglu, A., Kaymakoglu, S., Danalioglu, A., Akyuz, F., Ermis, F., Pinarbasi, B., Demir, K., Besisik, F., Cakaloglu, Y. (2013) Durability of Sustained Virologic Response in Chronic Hepatitis C. Gut and Liver, 7(4): 458-461
Welker, M., Zeuzem, S. (2008) Occult hepatitis C: How convincing are the current data?. Hepatology, 49(2): 665-675